Beneath the headline volatility, the deeper pattern is structural friction — the gap between where the science is pointing and where the regulatory architecture is willing to move. The 78% prediction that any psychedelic FDA approval will carry REMS requirements stricter than esketamine precedent — including certified treatment centers and minimum observation windows — is not a pessimistic forecast. It is the most realistic reading of institutional risk aversion combined with genuine, unresolved safety questions about uncontrolled settings. The Trump administration's emerging psychedelic initiative, predicted at 74% confidence to be framed narrowly around veteran opioid recovery and ibogaine rather than MDMA or consciousness, confirms the same logic: political navigation requires maximum coalition breadth and minimum liability surface. What is forming beneath all of this is a pathway that is real but deliberately narrow — a channel carved not by vision but by the specific shape of what the current moment's gatekeepers are willing to defend.
The human cost of structural friction is not abstract. Veterans who have exhausted every approved option are watching a policy negotiation determine whether ibogaine treatment becomes accessible in their lifetime or remains available only to those who can fund a flight to Mexico. Patients with treatment-resistant depression are doing the same math. The ketamine clinic patient who walks into an underregulated facility this week — because it is what is available, because the need is acute, because the barrier was low — is the human being most directly inside the 72% probability of a serious adverse event generating national media coverage before September. These are not cautionary statistics. They are people navigating a system that is moving, genuinely moving, but not yet moving with enough structure to hold them safely. The highest positive outcome here is not deregulation — it is the rapid construction of the scaffolding that makes access both real and safe at the same time.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
The current is already moving. You are already in it.
80%
No psychedelic drug moves out of Schedule I by end of 2026
The DEA (US Drug Enforcement Administration) controls whether drugs stay illegal or get reclassified—and they operate separately from the FDA (the US drug regulator) that approves medicines. Even if the FDA says a psychedelic medicine is safe and works, the DEA has to independently decide to move it to a lower schedule, a process that takes months or years. This matters because it means legal prescription use stays blocked even if the FDA green-lights it.
→ The FDA and DEA are two separate decision-makers, and the DEA shows no sign of moving psychedelics out of Schedule I in 2026 even if the FDA approves them.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
No psychedelic substance is rescheduled from Schedule I by DEA in calendar year 2026.. DEA retains independent scheduling authority separate from FDA approval. Under the current administration, DEA leadership has shown no appetite for rescheduling psychedelics. Even if FDA issues a positive NDA decision on MDMA or psilocybin, DEA's separate rescheduling process takes months to years a
76%
FDA-approved psychedelics require treatment centers and 6-hour monitoring
If the FDA approves a psychedelic medicine in 2026, it will come with a REMS program (a set of safety rules) requiring you to receive it only at certified treatment centers, not at home, and you'll have to stay under medical observation for at least 6 hours after you take it. The FDA learned this from esketamine (Spravato), where they required 2-hour monitoring, and they won't loosen those rules for a Schedule I drug because a bad headline about someone misusing it could sink the whole program.
→ Any FDA-approved psychedelic medicine will require you to use it in a certified clinic and stay under observation for several hours.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
If FDA approves any psychedelic therapeutic in 2026, the approval will include a REMS program requiring certified treatment centers AND a minimum supervised observation period of at least 6 hours post-administration.. FDA's esketamine (Spravato) REMS required in-office administration and 2-hour post-dose monitoring — FDA will not loosen that precedent for a Schedule I substance with greater abuse/diversion concern. Institutional risk aversion is high: a headline about unsupervised psychedelic misuse post-approval
73%
No published study proves psilocybin works for Alzheimer's before 2027
There are promising early hints that psilocybin might help Alzheimer's and dementia patients, but no rigorous controlled trial (the gold standard for proof) has been completed and published yet. Running these trials is brutally hard: people with dementia can't reliably consent, recruiting enough patients takes years, and following them safely for months after treatment is medically complex. Even well-funded trials starting now won't finish, analyze, and publish results by the end of 2026.
→ Rigorous proof that psilocybin treats Alzheimer's won't appear in published research until 2027 at the earliest.
Resolves: 2027-12-31 · Global
RESEARCH
the precise call ▾
No peer-reviewed controlled trial (Phase II or higher) replicating psilocybin efficacy in Alzheimer's disease or dementia publishes results before 2027-12-31.. The Alzheimer's-psilocybin signal is currently at case-report or early preclinical stage. Controlled trials in this population face extraordinary recruitment challenges (informed consent with cognitive impairment), safety hurdles, and lengthy IRB timelines. Even aggressively funded trials initiated
72%
Federal psychedelic research plan focuses on veterans and avoids MDMA
If the White House announces a psychedelic research initiative before August 2026, it will be framed around helping veterans with opioid addiction and PTSD, not recreational drug legalization. It will probably mention psilocybin or ibogaine but avoid naming MDMA (the party drug), because that association polls badly across party lines. This framing lets politicians claim interest in psychedelic medicine as helping veterans while avoiding 'rave drug' attacks.
→ Any federal psychedelic research plan will be sold as helping veterans kick opioids, not as drug legalization.
Resolves: 2026-08-01 · USA
POLICY
the precise call ▾
Any White House or federal executive-branch psychedelic research initiative announced before 2026-08-01 will be explicitly framed around veteran opioid/addiction recovery and will not name MDMA as a target compound.. Political coalition math is clear: ibogaine and psilocybin carry less cultural baggage in conservative media than MDMA, which has persistent 'rave drug' associations. Veteran opioid recovery polls strongly across partisan lines and provides a defensible framing for what would otherwise be attacked a
68%
A large pharma company buys ketamine clinic infrastructure by September 2026
A big pharmaceutical company (market value over $1 billion) will announce a deal to buy, partner with, or license a ketamine clinic operator—outfits like Field Trip or Ketamine Wellness Centers. Ketamine is already legal (Schedule III, less restricted), generates real clinic revenue, and poses no Schedule I legal risk, so pharma companies view clinic infrastructure as a safer way to enter the psychedelic space without the regulatory chaos of Schedule I compounds. This could happen by September 2026.
→ Big pharma will likely buy ketamine clinic operators by September 2026 as a legally safe way into the psychedelic market.
Resolves: 2026-09-30 · USA
MARKET
the precise call ▾
At least one pharma company with >$1B market cap announces a licensing deal, acquisition, or formal partnership targeting ketamine or esketamine clinic infrastructure by 2026-09-30.. Ketamine is already Schedule III, generating clinic revenue, and legally de-risked relative to Schedule I psychedelics. The clinic infrastructure buildout (Field Trip, Ketamine Wellness Centers, etc.) represents an acqui-hire opportunity for pharma seeking psychedelic-adjacent positioning without Sc